GlucoTrack, Inc. (NASDAQ: GCTK) Stock Competitors & Peer Comparison
See GCTK's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GCTK and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GCTK | $0.29 | -6.76% | 165.2K | -0.01 | -$20.89 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
GCTK vs BDX Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas BDX's P/E ratio is 11.62. In terms of profitability, GCTK's ROE is -5.82%, compared to BDX's ROE of +0.05%. Regarding short-term risk, GCTK is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
GCTK vs BDXA Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas BDXA's P/E ratio is 45.70. In terms of profitability, GCTK's ROE is -5.82%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, GCTK is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
GCTK vs MDLN Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas MDLN's P/E ratio is 45.06. In terms of profitability, GCTK's ROE is -5.82%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, GCTK is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
GCTK vs WST Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas WST's P/E ratio is 41.19. In terms of profitability, GCTK's ROE is -5.82%, compared to WST's ROE of +0.19%. Regarding short-term risk, GCTK is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
GCTK vs HOLX Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas HOLX's P/E ratio is 31.54. In terms of profitability, GCTK's ROE is -5.82%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, GCTK is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
GCTK vs COO Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas COO's P/E ratio is 15.42. In terms of profitability, GCTK's ROE is -5.82%, compared to COO's ROE of +0.03%. Regarding short-term risk, GCTK is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
GCTK vs BDXB Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas BDXB's P/E ratio is 7.60. In terms of profitability, GCTK's ROE is -5.82%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, GCTK is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
GCTK vs BAX Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas BAX's P/E ratio is 10.77. In terms of profitability, GCTK's ROE is -5.82%, compared to BAX's ROE of -0.16%. Regarding short-term risk, GCTK is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
GCTK vs ATR Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ATR's P/E ratio is 23.13. In terms of profitability, GCTK's ROE is -5.82%, compared to ATR's ROE of +0.14%. Regarding short-term risk, GCTK is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
GCTK vs AVTR Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas AVTR's P/E ratio is 13.46. In terms of profitability, GCTK's ROE is -5.82%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, GCTK is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
GCTK vs RGEN Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas RGEN's P/E ratio is 73.31. In terms of profitability, GCTK's ROE is -5.82%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, GCTK is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
GCTK vs TFX Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas TFX's P/E ratio is 12.32. In terms of profitability, GCTK's ROE is -5.82%, compared to TFX's ROE of -0.28%. Regarding short-term risk, GCTK is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
GCTK vs BLCO Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas BLCO's P/E ratio is 24.88. In terms of profitability, GCTK's ROE is -5.82%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, GCTK is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
GCTK vs STVN Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas STVN's P/E ratio is 31.81. In terms of profitability, GCTK's ROE is -5.82%, compared to STVN's ROE of +0.10%. Regarding short-term risk, GCTK is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
GCTK vs MMSI Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas MMSI's P/E ratio is 19.01. In terms of profitability, GCTK's ROE is -5.82%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, GCTK is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
GCTK vs ICUI Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ICUI's P/E ratio is 19.66. In terms of profitability, GCTK's ROE is -5.82%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, GCTK is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
GCTK vs HAE Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas HAE's P/E ratio is 15.86. In terms of profitability, GCTK's ROE is -5.82%, compared to HAE's ROE of +0.11%. Regarding short-term risk, GCTK is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
GCTK vs XRAY Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas XRAY's P/E ratio is 9.04. In terms of profitability, GCTK's ROE is -5.82%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, GCTK is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
GCTK vs LMAT Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas LMAT's P/E ratio is 37.05. In terms of profitability, GCTK's ROE is -5.82%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, GCTK is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
GCTK vs PLSE Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas PLSE's P/E ratio is -27.48. In terms of profitability, GCTK's ROE is -5.82%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, GCTK is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
GCTK vs ATRC Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, GCTK's ROE is -5.82%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, GCTK is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
GCTK vs BLFS Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas BLFS's P/E ratio is -141.85. In terms of profitability, GCTK's ROE is -5.82%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, GCTK is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
GCTK vs AZTA Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas AZTA's P/E ratio is 60.82. In terms of profitability, GCTK's ROE is -5.82%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, GCTK is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
GCTK vs KMTS Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas KMTS's P/E ratio is -8.92. In terms of profitability, GCTK's ROE is -5.82%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, GCTK is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
GCTK vs STAA Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas STAA's P/E ratio is 41.02. In terms of profitability, GCTK's ROE is -5.82%, compared to STAA's ROE of -0.06%. Regarding short-term risk, GCTK is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
GCTK vs QDEL Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas QDEL's P/E ratio is 11.98. In terms of profitability, GCTK's ROE is -5.82%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, GCTK is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
GCTK vs ATRI Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ATRI's P/E ratio is 64.50. In terms of profitability, GCTK's ROE is -5.82%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, GCTK is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
GCTK vs ANGO Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ANGO's P/E ratio is -34.85. In terms of profitability, GCTK's ROE is -5.82%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, GCTK is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
GCTK vs NNNN Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas NNNN's P/E ratio is 145.38. In terms of profitability, GCTK's ROE is -5.82%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, GCTK is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
GCTK vs OSUR Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas OSUR's P/E ratio is -4.78. In terms of profitability, GCTK's ROE is -5.82%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, GCTK is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
GCTK vs SMTI Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas SMTI's P/E ratio is -426.00. In terms of profitability, GCTK's ROE is -5.82%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, GCTK is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
GCTK vs UTMD Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas UTMD's P/E ratio is 19.86. In terms of profitability, GCTK's ROE is -5.82%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, GCTK is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
GCTK vs INFU Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas INFU's P/E ratio is 23.97. In terms of profitability, GCTK's ROE is -5.82%, compared to INFU's ROE of +0.14%. Regarding short-term risk, GCTK is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
GCTK vs KRMD Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas KRMD's P/E ratio is -95.75. In terms of profitability, GCTK's ROE is -5.82%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, GCTK is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
GCTK vs PDEX Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas PDEX's P/E ratio is 19.34. In terms of profitability, GCTK's ROE is -5.82%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, GCTK is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
GCTK vs MBOT Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas MBOT's P/E ratio is -6.58. In terms of profitability, GCTK's ROE is -5.82%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, GCTK is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
GCTK vs AKYA Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas AKYA's P/E ratio is -1.34. In terms of profitability, GCTK's ROE is -5.82%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, GCTK is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
GCTK vs STSS Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas STSS's P/E ratio is -0.02. In terms of profitability, GCTK's ROE is -5.82%, compared to STSS's ROE of -1.66%. Regarding short-term risk, GCTK is more volatile compared to STSS. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
GCTK vs DXR Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas DXR's P/E ratio is 27.33. In terms of profitability, GCTK's ROE is -5.82%, compared to DXR's ROE of +0.22%. Regarding short-term risk, GCTK is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
GCTK vs OMIC Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas OMIC's P/E ratio is -0.58. In terms of profitability, GCTK's ROE is -5.82%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, GCTK is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
GCTK vs IGAP Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas IGAP's P/E ratio is -10.52. In terms of profitability, GCTK's ROE is -5.82%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, GCTK is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
GCTK vs NEPH Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas NEPH's P/E ratio is 50.86. In terms of profitability, GCTK's ROE is -5.82%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, GCTK is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
GCTK vs MLSS Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas MLSS's P/E ratio is -6.50. In terms of profitability, GCTK's ROE is -5.82%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, GCTK is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
GCTK vs POCI Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas POCI's P/E ratio is -6.07. In terms of profitability, GCTK's ROE is -5.82%, compared to POCI's ROE of -0.37%. Regarding short-term risk, GCTK is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
GCTK vs SDC Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas SDC's P/E ratio is -0.03. In terms of profitability, GCTK's ROE is -5.82%, compared to SDC's ROE of -1.96%. Regarding short-term risk, GCTK is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for GCTK.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
GCTK vs HBIO Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas HBIO's P/E ratio is -16.81. In terms of profitability, GCTK's ROE is -5.82%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, GCTK is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
GCTK vs IVC Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas IVC's P/E ratio is -0.79. In terms of profitability, GCTK's ROE is -5.82%, compared to IVC's ROE of -0.46%. Regarding short-term risk, GCTK is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
GCTK vs RVP Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas RVP's P/E ratio is -2.06. In terms of profitability, GCTK's ROE is -5.82%, compared to RVP's ROE of -0.08%. Regarding short-term risk, GCTK is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
GCTK vs ZJYL Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, GCTK's ROE is -5.82%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, GCTK is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
GCTK vs FEMY Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas FEMY's P/E ratio is -10.25. In terms of profitability, GCTK's ROE is -5.82%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, GCTK is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
GCTK vs RGNT Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas RGNT's P/E ratio is -0.08. In terms of profitability, GCTK's ROE is -5.82%, compared to RGNT's ROE of N/A. Regarding short-term risk, GCTK is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
GCTK vs NSTG Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas NSTG's P/E ratio is -0.03. In terms of profitability, GCTK's ROE is -5.82%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, GCTK is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for GCTK.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
GCTK vs NXGL Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas NXGL's P/E ratio is -1.13. In terms of profitability, GCTK's ROE is -5.82%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, GCTK is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
GCTK vs POAI Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas POAI's P/E ratio is -0.03. In terms of profitability, GCTK's ROE is -5.82%, compared to POAI's ROE of -107.05%. Regarding short-term risk, GCTK is more volatile compared to POAI. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
GCTK vs LUCY Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas LUCY's P/E ratio is -0.39. In terms of profitability, GCTK's ROE is -5.82%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, GCTK is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
GCTK vs MHUA Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas MHUA's P/E ratio is 0.25. In terms of profitability, GCTK's ROE is -5.82%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, GCTK is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
GCTK vs NXGLW Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, GCTK's ROE is -5.82%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, GCTK is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
GCTK vs GMVD Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas GMVD's P/E ratio is -0.01. In terms of profitability, GCTK's ROE is -5.82%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, GCTK is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for GCTK.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
GCTK vs GMVDW Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas GMVDW's P/E ratio is N/A. In terms of profitability, GCTK's ROE is -5.82%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, GCTK is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for GCTK.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
GCTK vs AVGR Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas AVGR's P/E ratio is -0.05. In terms of profitability, GCTK's ROE is -5.82%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, GCTK is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for GCTK.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
GCTK vs LUCYW Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, GCTK's ROE is -5.82%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, GCTK is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for GCTK.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
GCTK vs ATRS Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ATRS has a market cap of 0. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ATRS's P/E ratio is 14.95. In terms of profitability, GCTK's ROE is -5.82%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, GCTK is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
GCTK vs ALOG Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, ALOG has a market cap of 0. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas ALOG's P/E ratio is 40.93. In terms of profitability, GCTK's ROE is -5.82%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, GCTK is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check ALOG's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
GCTK vs HRC Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, HRC has a market cap of 0. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas HRC's P/E ratio is 41.92. In terms of profitability, GCTK's ROE is -5.82%, compared to HRC's ROE of +0.14%. Regarding short-term risk, GCTK is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check HRC's competition here
Invuity, Inc. (NASDAQ: IVTY)
GCTK vs IVTY Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, IVTY has a market cap of 0. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas IVTY's P/E ratio is -3.80. In terms of profitability, GCTK's ROE is -5.82%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, GCTK is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check IVTY's competition here
Apria, Inc. (NASDAQ: APR)
GCTK vs APR Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, APR has a market cap of 0. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas APR's P/E ratio is 22.59. In terms of profitability, GCTK's ROE is -5.82%, compared to APR's ROE of +9.81%. Regarding short-term risk, GCTK is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
GCTK vs IIN Comparison July 2026
GlucoTrack, Inc. (NASDAQ: GCTK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 165.2K. In comparison, IIN has a market cap of 0. Regarding current trading prices, GCTK is priced at $0.29 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of -0.01, whereas IIN's P/E ratio is 226.45. In terms of profitability, GCTK's ROE is -5.82%, compared to IIN's ROE of -0.00%. Regarding short-term risk, GCTK is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for GCTK.Check IIN's competition here